A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-06-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-0909PMID 27281561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

  2016cited by this paper
• A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

  2016cited by this paper
• Circulating tumor cells in breast cancer--current status and perspectives.

  2016cited by this paper
• Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

  2015cited by this paper
• Crizotinib in ROS1-rearranged non-small-cell lung cancer.

  2015cited by this paper
• Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non–small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results

  2015cited by this paper
• Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease

  2015cited by this paper
• Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

  2015cited by this paper
• Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

  2015influential reference
• Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M

  2015cited by this paper
• Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

  2015cited by this paper
• Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

  2014cited by this paper
• The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: From Enumeration to Molecular Characterization

  2014cited by this paper
• Crizotinib in ROS1-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment

  2014cited by this paper
• Microfluidic, marker-free isolation of circulating tumor cells from blood samples

  2014cited by this paper
• Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

  2014cited by this paper
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

  2013cited by this paper
• Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

  2013cited by this paper
• Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.

  2013cited by this paper
• Liquid biopsy: monitoring cancer-genetics in the blood

  2013cited by this paper
• Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.

  2013cited by this paper
• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.

  2012cited by this paper
• Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

  2012cited by this paper
• Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.

  2011cited by this paper
• Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

  2011cited by this paper
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2011cited by this paper
• Circulating tumor cells: approaches to isolation and characterization

  2011cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

  2008cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

  2004cited by this paper

• Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients

  2025cites this paper
• Circulating Molecular Biomarkers for the Diagnosis and Monitoring of NSCLC—A Review

  2025cites this paper
• KRAS ctDNA Detection in Patients With Resectable Lung Adenocarcinoma.

  2025cites this paper
• The emerging role of cell-free DNA as a molecular marker for duodenal adenocarcinoma

  2024cites this paper
• Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment

  2024cites this paper
• Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments

  2024cites this paper
• Exosomal ncRNAs in liquid biopsies for lung cancer.

  2024cites this paper
• Liquid Biopsies in Lung Cancer

  2023cites this paper
• DELFMUT: duplex sequencing-oriented depth estimation model for stable detection of low-frequency mutations

  2023cites this paper
• Rapid detection of EGFR mutation in CTCs based on a double spiral microfluidic chip and the real-time RPA method

  2023cites this paper
• Liquid biopsy: creating opportunities in brain space

  2023cites this paper
• Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome.

  2022cites this paper
• A multiple detection method for distinguishing gene mutations based on melting curves of extended quenching probes

  2022cites this paper
• Circulating Cell-Free Genomic DNA Is Associated with an Increased Risk of Dementia and with Change in Cognitive and Physical Function

  2022cites this paper
• Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer

  2022cites this paper
• Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer

  2022cites this paper
• Clinical utility of analyzing circulating tumor DNA in patients with non-small cell lung carcinoma

  2022cites this paper
• Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers

  2022cites this paper
• Challenges and future directions

  2022cites this paper
• Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients

  2021cites this paper
• Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design

  2021influential citation
• Circulating DNA Quantification

  2021cites this paper
• Emerging role of circulating tumor cells in immunotherapy

  2021cites this paper
• Progress and application of circulating tumor cells in non-small cell lung cancer

  2021cites this paper
• Sensitivity assessment of workflows detecting rare circulating cell-free DNA targets: A study design proposal

  2021cites this paper
• CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib

  2021cites this paper
• Biomarkers and Target Therapy for Lung Cancer

  2021cites this paper
• Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis

  2021cites this paper
• Cell-Free DNA: Hope and Potential Application in Cancer

  2021cites this paper
• Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability

  2021cites this paper
• Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients

  2021cites this paper
• Sensitive Detection of KRAS Mutations by Clustered Regularly Interspaced Short Palindromic Repeats

  2021cites this paper
• Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential

  2020cites this paper
• Is tissue still the issue in detecting molecular alterations in lung cancer?

  2020cites this paper
• Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages

  2020cites this paper
• Circulating cell-free tumor DNA analysis in pediatric cancers.

  2020cites this paper
• Precision Medicine in Lung Cancer: Challenges and Opportunities in Diagnostic and Therapeutic Purposes

  2020cites this paper
• Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer

  2020cites this paper
• Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy

  2020cites this paper
• Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports

  2020cites this paper
• Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer Patients

  2020cites this paper
• Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

  2020cites this paper
• Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer

  2020cites this paper
• The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review

  2020cites this paper
• Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

  2019cites this paper
• Liquid biopsies

  2019influential citation
• Ultrasensitive and quantitative detection of EGFR mutations in plasma samples from patients with non-small-cell lung cancer using a dual PNA clamping-mediated LNA-PNA PCR clamp.

  2019cites this paper
• Application of cell-free DNA for genomic tumor profiling: a feasibility study

  2019cites this paper
• Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors.

  2019cites this paper
• Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

  2019cites this paper
• Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review.

  2019cites this paper
• Update on liquid biopsy in clinical management of non-small cell lung cancer

  2019influential citation
• Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

  2019cites this paper
• 1 Intrinsic resistance to EGFR-tyrosine kinase 2 inhibitors in EGFR-mutant non-small cell lung 3 cancer : differences and similarities with acquired 4 resistance 5

  2019cites this paper
• Translational and basic science opportunities in palliative care and radiation oncology.

  2019cites this paper
• Liquid biopsy: a holy grail for cancer detection.

  2019cites this paper
• The current status of the clinical utility of liquid biopsies in cancer

  2019cites this paper
• Perspective: Cellular and Molecular Profiling Technologies in Personalized Oncology

  2019cites this paper
• The Factors Predicting Concordant Epidermal Growth Factor Receptor (EGFR) Mutation Detected in Liquid/Tissue Biopsy and the Related Clinical Outcomes in Patients of Advanced Lung Adenocarcinoma with EGFR Mutations

  2019cites this paper
• Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.

  2019cites this paper
• OTT_A_203070 5097..5109

  2019influential citation
• Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.

  2019cites this paper
• A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

  2018cites this paper
• Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients

  2018cites this paper
• Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

  2018cites this paper
• Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!

  2018cites this paper
• Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration☆

  2018cites this paper
• Deoxyribonuclease I Activity, Cell-Free DNA, and Risk of Liver Cancer in a Prospective Cohort

  2018cites this paper
• Cell-Free DNA: Applications in Different Diseases.

  2018cites this paper
• Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

  2018cites this paper
• Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma

  2018cites this paper
• Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer

  2018cites this paper
• Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection

  2018cites this paper
• Correlation between progression‐free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced‐stage EGFR‐mutated non‐small cell lung cancer

  2018cites this paper
• Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer

  2018cites this paper
• Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)

  2018cites this paper
• The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy.

  2018cites this paper
• 晚期肺腺癌患者一线治疗前后EGFR基因突变差异性分析

  2018cites this paper
• Advances in Circulating Tumor DNA Analysis.

  2017cites this paper
• Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy

  2017influential citation
• Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration

  2017cites this paper
• [Current progress in research of circulating tumor cells].

  2017cites this paper
• Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients

  2017cites this paper
• Towards a comprehensive framework for cell-free DNA analysis: lessons from TRACERx.

  2017cites this paper
• Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring

  2017cites this paper
• Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.

  2017cites this paper
• Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma

  2017cites this paper
• Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms.

  2017cites this paper
• Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.

  2017cites this paper
• Cell-Free DNA in Oncology: Gearing up for Clinic

  2017cites this paper
• Current and Emerging Applications of Droplet Digital PCR in Oncology

  2017cites this paper
• Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC

  2017cites this paper
• Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring

  2017cites this paper
• Blood collection in cell-stabilizing tubes does not impact germline DNA quality for pediatric patients

  2017cites this paper
• Biology and clinical significance of circulating tumor cell subpopulations in lung cancer.

  2017cites this paper
• Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management

  2017cites this paper
• Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment

  2017cites this paper
• Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms

  2017cites this paper
• Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer

  2017cites this paper
• EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial

  2017cites this paper